|Cancer Information Highlights|
|From the National Cancer Institute|
|Updating you about cancer causes, prevention, screening, treatment, coping, and more|
|New from NCI|
The NCI-MATCH study is now on hold during a pre-planned pause in enrollment. In this update, Dr. Barbara Conley (NCI-MATCH Study Chair) explains the trial's status and plans for its future.
|Phases of Clinical Trials Video|
Clinical trials to test new cancer treatments involve a series of steps, called phases. This video explains what's involved in the three main phases.
|NCI Budget Fact Book Released|
The Budget Fact Book provides a summary of how NCI distributed its fiscal year 2014 $4.9 billion budget among its research programs. It also describes NCI funding policies related to research grant awards.
We've renamed our PDQ "Pain" summary and updated the information about how cancer pain is assessed, drugs used to relieve cancer pain, and treatment in older patients.
|Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer|
We've updated our PDQ summary with newer images depicting all stages of this cancer.
We've updated our PDQ summary to include intravitreal chemotherapy as a treatment for progressive or recurrent retinoblastoma, a cancer of the eye.
We've added the recent approval from the Food and Drug Administration (FDA) for the use of this drug to treat liposarcoma, a type of soft tissue sarcoma.
|Also of Interest|
|More about the NCI-MATCH Trial|
Here we explain what the NCI-MATCH Trial is, why it is unique, and how it works.
|Soft Tissue Sarcoma|
Eribulin mesylate (Halaven) was recently approved to treat liposarcoma. It is the first drug proven to help patients with liposarcoma live longer. Liposarcoma is a type of soft tissue sarcoma. Learn about the different types of soft tissue sarcoma and how they are treated.
|Common Cancer Types|
This page lists incidence and mortality statistics for cancers that are diagnosed most often in the United States. We've recently updated the page with 2016 estimates.
Statement from FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., and Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health, on the agency’s continued efforts to protect women’s health and enhance safety information available to patients considering breast implants
Hace 1 hora